FoxHollow seek US nod for NightHawk:
This article was originally published in Clinica
FoxHollow Technologies has submitted to the US FDA a 510(k) marketing application for its NightHawk system for visualising and excising plaque from peripheral arteries. The product brings together optical coherence tomography (OCT) with the firm's FDA-cleared SilverHawk plaque excision system. It uses fibre-optic technology embedded in the catheter and allows the physician to visualise in real-time the vascular morphology and wall structures. The OCT-embedded catheters are designed for use as an adjunct to conventional angiography to provide an image of the vessel lumen and wall structures. Separately, the Redwood City, California firm has launched a faster and easier-to-use version of SilverHawk, called SilverHawk SXL.
You may also be interested in...
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.
Colgate Zero toothpastes and mouthwashes promote what’s missing; Tom’s of Maine natural personal care expands with prebiotic toothpaste, deodorant and hand soap; Gaia adds hemp to its herbs; and Church & Dwight goes environmentally friendly with VitaFusion Goodness supplements, adds CBD versions to line, too.